{
  "abstract": "N⁶-methyladenosine (m⁶A), the most prevalent internal modification in eukaryotic RNA, has emerged as a key epitranscriptomic regulator in the central nervous system, coordinating gene expression programs that govern neural development, synaptic plasticity, and neuronal adaptation throughout the lifespan. This review synthesizes emerging evidence that m⁶A dysregulation represents a shared epitranscriptomic mechanism linking neurodevelopmental and neurodegenerative disorders, highlighting a mechanistic convergence that bridges these traditionally distinct disease categories. Dysregulation of m⁶A-mediated control of neurogenesis, synaptic maturation, and dopaminergic development has been implicated in neurodevelopmental disorders, including autism spectrum disorder, attention-deficit/hyperactivity disorder, and intellectual disability. In neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, m⁶A dysregulation mediates multiple interconnected pathogenic processes, including neuroinflammation, mitochondrial dysfunction, tau hyperphosphorylation and aggregation, α-synuclein dysregulation, and impaired neuronal repair. Environmental stressors and metabolic perturbations modulate m⁶A modification patterns, suggesting that gene-environment interactions contribute to disease susceptibility through epitranscriptomic mechanisms. m⁶A modification functions as a dynamic molecular switch governing neural plasticity and circuit function across early development, adulthood, and aging, and its dysregulation predisposes individuals to neurological disease manifestation throughout the lifespan. Advances in cell-type-specific and circuit-resolved m⁶A profiling will deepen our understanding of m⁶A dysregulation and strengthen its translational potential as both a diagnostic biomarker and a therapeutic target in neurological diseases. Furthermore, we evaluate pharmacological and molecular strategies targeting m⁶A regulatory machinery, including the writers METTL3/METTL14, the erasers FTO/ALKBH5, and reader proteins, as promising therapeutic approaches to restore aberrant neuronal circuit function in neurodevelopmental and neurodegenerative disorders.",
  "abstract_shown": true,
  "affiliations": [
    "College of Osteopathic Medicine, Kansas City University, Farber-McIntire Campus, 2901 St. Johns Blvd, Joplin, MO 64804-1598, USA.",
    "The Human Physiology Program, Sargent College of Health & Rehabilitation Sciences, Boston University, 635 Commonwealth Avenue, Boston, MA 02215-1610, USA.",
    "College of Pharmacy, Western University, California Campus, 309 E. Second St., Pomona, CA 91766-1854, USA.",
    "Department of Psychiatry, Boston University Chobanian & Avedisian School of Medicine, 72 East Concord Street, Boston, MA 02118-2526, USA.",
    "The Biomedical Genetics Section, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, 72 East Concord Street, Boston, MA 02118-2526, USA."
  ],
  "article_type": "review article",
  "arxiv": null,
  "author_total": 6,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Ambrose Loc Ngo"
    },
    {
      "affs": [
        1
      ],
      "name": "Xuemei Qu"
    },
    {
      "affs": [
        0
      ],
      "name": "Niki Gharavi Alkhansari"
    },
    {
      "affs": [
        2
      ],
      "name": "Linda Nguyen"
    },
    {
      "affs": [
        0
      ],
      "name": "Uyen Tam Nguyen",
      "orcid": "0009-0006-9239-8686"
    },
    {
      "affs": [
        3,
        4
      ],
      "name": "Huiping Zhang",
      "orcid": "0000-0002-4902-0104"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/c26srd5jaxgnf.bib",
  "cited_by": 0,
  "doi": "10.3390/epigenomes10040062",
  "fulltext_url": "https://europepmc.org/articles/PMC13692518",
  "id": "c26srd5jaxgnf",
  "issns": [
    "2075-4655"
  ],
  "landing_url": "https://europepmc.org/article/MED/42924721",
  "language": "eng",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "1312|RNA modifications and cancer"
    ]
  ],
  "openalex": "W7220392655",
  "pdf_url": "https://europepmc.org/articles/PMC13692518?pdf=render",
  "pmcid": "PMC13692518",
  "pmid": "42924721",
  "published": "2026-10-03",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/c26srd5jaxgnf.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:20:36Z",
      "native_id": "MED:42924721",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42924721"
    }
  ],
  "subjects": [
    {
      "field": "biochemistry",
      "origin": "openalex:1312|RNA modifications and cancer",
      "subfield": "molecular-biology"
    }
  ],
  "title": "Dynamic m⁶A Methylation in Neurodevelopmental and Neurodegenerative Disorders.",
  "title_text": "Dynamic m⁶A Methylation in Neurodevelopmental and Neurodegenerative Disorders.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:20:36Z",
  "url": "https://research.draconitic.com/paper/c26srd5jaxgnf",
  "venue": "Epigenomes",
  "versions": []
}